AT-007 in Adult Subjects With Classic Galactosemia (CG)
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is a 12-month open-label extension (OLE) study of AT-007 in adult subjects with CG
who previously participated in Study AT-007-1001 Part D and/or Part D Extension.
The study is designed to assess the long-term safety of AT-007 in subjects with CG as well as
the pharmacodynamics (PD) (inhibition of galactitol) and PK of AT-007. The effect of 12-month
treatment with AT-007 on the levels of galactose and other galactose metabolites in subjects
with CG will also be evaluated.